Articles

Trump and Harris would add trillions to the national debt. Here’s why it could lead to higher costs for households.

Analysts say much of the recent inflation crisis was driven by government budget deficit

‘A disappointment to home buyers’: Mortgage rates surge to a two-month high

The 30-year mortgage rate is averaging 6.44%, Freddie Mac said in its latest weekly survey on Thursday.

U.S. business inventories expand for fifth straight month in August, bolstering economic outlook

Business inventories rose 0.3% for the second straight month and for the fifth straight month overall in August, the Commerce Department said Thursday.

A drop in mortgage rates has failed to ignite home-buying demand, but builders remain optimistic

Builder sentiment inched up in October, the National Association of Home Builders said.

The world isn’t prepared for an aging population — but it’s actually a huge opportunity

By the year 2047, the global population will have more people in retirement age than young people.

Nvidia’s stock tracks toward record as TSMC sees AI chip market still booming

All members of the PHLX Semiconductor Index were in positive territory Thursday as TSMC offered upbeat commentary on the sector.

U.S. industrial output falls in September, held down by Boeing strike and hurricanes

Production down 0.3%, slightly below forecast

Gevo stock soars on $1.46 billion DOE loan for sustainable aviation fuel plant

Shares of Gevo Inc. are climbing 38.2% in premarket trades Thursday after the renewable chemicals and biofuels company received a commitment for a $1.46 billion loan from the U.S. Department of Energy.

Jobless claims retreat after last week’s sharp increase

One week after hitting the highest level in more than a year, initial jobless claims retreated by 19,000 to 241,000, the Labor Department said Thursday.  

Philadelphia Fed’s factory gauge jumps in October

Index rises to 10.3, second straight monthly gain

Retail sales post solid gain in September

Sales up 0.4%, above market forecasts

AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
1 225 226 227 228 229 1,851